Artielle ImmunoTherapeutics, Inc. develops a platform of biologic drugs to treat inflammatory and degenerative diseases worldwide. The company focuses on neuro-inflammatory and degenerative diseases, including multiple sclerosis, optic neuritis, methamphetamine addiction, and stroke; and products to treat rheumatoid arthritis, uveitis, age-related macular degeneration, and celiac diseases. Artielle ImmunoTherapeutics, Inc. was founded in 2004 and is based in Tigard, Oregon.